# A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa

> **NCT02494570** · PHASE2 · COMPLETED · sponsor: **Aadi Bioscience, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Malignant PEComa

## Interventions

- **DRUG:** nab-Sirolimus

## Key facts

- **NCT ID:** NCT02494570
- **Lead sponsor:** Aadi Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2021-11
- **Final completion:** 2022-04
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02494570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02494570, "A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02494570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*